Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends
Anti-metastatic therapeutics commonly use those compounds that recognize the biomarkers
involved in different signaling pathways of cancer cell metastasis, including tumor …
involved in different signaling pathways of cancer cell metastasis, including tumor …
[HTML][HTML] The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study
D Sweed, SS El Gammal, S Kilany… - …, 2023 - ncbi.nlm.nih.gov
Background: The most common types of primary malignant liver tumours are hepatocellular
carcinoma (HCC) and cholangiocarcinoma (CCA). Treatment options for patients who are …
carcinoma (HCC) and cholangiocarcinoma (CCA). Treatment options for patients who are …
Emerging Antineoplastic Potential of Nanoparticles Against Different Types of Cancer
VK Garg, A Sood, D Kapoor, K Sak… - Nanotherapeutics in …, 2022 - taylorfrancis.com
In 2020, an estimated 19.3 million new cancer cases with almost 10.0 million cancer-related
deaths were reported worldwide. One promising approach along this road involves the …
deaths were reported worldwide. One promising approach along this road involves the …
[图书][B] Nanotherapeutics in Cancer: Materials, Diagnostics, and Clinical Applications
HS Tuli - 2022 - api.taylorfrancis.com
The applications of nanoparticulate drug delivery have received significant attention in the
field of cancer diagnosis and treatment. Owing to their unique features and design …
field of cancer diagnosis and treatment. Owing to their unique features and design …